VYNE Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
YARW$15.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements Of Changes In Stockholders' Equity
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(U.S. dollars in thousands, except share data)
| Common stock · Additional paid-incapital · Accumulated other comprehensive income (loss) · Accumulated deficit · Total Stockholders' Equity | ||||||
|---|---|---|---|---|---|---|
| Number of Shares · Amount · Amount | ||||||
| BALANCE AT JANUARY 1, 2024 | 14,098,888 | $1 | $780,044 | $26 | $(691,336) | $88,735 |
| CHANGES DURING THE PERIOD: | ||||||
| Net loss | — | — | — | — | (27,812) | (27,812) |
| Vesting of restricted stock units, net of withholding for tax, and shares issued under employee stock purchase plan | 12,722 | — | 2 | — | — | 2 |
| Stock-based compensation | — | — | 2,604 | — | — | 2,604 |
| Cashless exercise of pre-funded warrants | 639,823 | — | — | — | — | — |
| Unrealized gains from marketable securities | — | — | — | 8 | — | 8 |
| BALANCE AT SEPTEMBER 30, 2024 | 14,751,433 | $1 | $782,650 | $34 | $(719,148) | $63,537 |
| BALANCE AT JANUARY 1, 2025 | 14,830,013 | $1 | $783,235 | $20 | $(731,170) | $52,086 |
| CHANGES DURING THE PERIOD: | ||||||
| Net loss | — | — | — | — | (21,646) | (21,646) |
| Vesting of restricted stock units, net of withholding for tax, and shares issued under employee stock purchase plan | 162,933 | — | (117) | — | — | (117) |
| Stock-based compensation | — | — | 1,779 | — | — | 1,779 |
| Cashless exercise of pre-funded warrants | 16,779,958 | 2 | — | — | — | 2 |
| Unrealized losses from marketable securities | — | — | — | (16) | — | (16) |
| BALANCE AT SEPTEMBER 30, 2025 | 31,772,904 | $3 | $784,897 | $4 | $(752,816) | $32,088 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(U.S. dollars in thousands, except share data)
| Common stock · Additional paid-incapital · Accumulated other comprehensive income (loss) · Accumulated deficit · Total Stockholders' Equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Number of Shares · Amount · Amount | |||||||||
| BALANCE AT JULY 1, 2024 | 14,536,124 | $1 | $781,917 | $(58) | $(706,991) | $74,869 | |||
| CHANGES DURING THE PERIOD: | |||||||||
| Net loss | — | — | — | — | (12,157) | (12,157) | |||
| Vesting of restricted stock units, net of withholding for tax, and shares issued under employee stock purchase plan | 2,036 | — | (1) | — | — | (1) | |||
| Stock-based compensation | — | — | 734 | — | — | 734 | |||
| Cashless exercise of pre-funded warrants | 213,273 | — | — | — | — | — | |||
| Unrealized gains from marketable securities | — | — | — | 92 | — | 92 | |||
| BALANCE AT SEPTEMBER 30, 2024 | 14,751,433 | $1 | $782,650 | $34 | $(719,148) | $63,537 | |||
| BALANCE AT JULY 1, 2025 | 19,773,784 | $2 | $784,418 | $(2) | $(745,536) | $38,882 | |||
| CHANGES DURING THE PERIOD: | |||||||||
| Net loss | — | — | — | — | (7,280) | (7,280) | |||
| Vesting of restricted stock units, net of withholding for tax, and shares issued under employee stock purchase plan | 32,773 | — | (8) | — | — | (8) | |||
| Stock-based compensation | — | — | 487 | — | — | 487 | |||
| Cashless exercise of pre-funded warrants | 11,966,347 | 1 | — | — | 1 | ||||
| Unrealized gains from marketable securities | — | — | — | 6 | — | 6 | |||
| BALANCE AT SEPTEMBER 30, 2025 | 31,772,904 | $3 | $784,897 | $4 | $(752,816) | $32,088 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.